Refine Results
  1. "Annals of Oncology"
Formats
  1. Meeting Abstract (688)
  2. Journal Article (344)
  3. Conference Paper (8)
  4. Editorial (4)
  5. Guidelines (4)
  6. Review (3)
  7. Correspondence (1)
Groups
  1. Solid Tumor Oncology Division (758)
  2. Genitourinary Oncology Service (209)
  3. Gastrointestinal Oncology Service (174)
  4. Thoracic Oncology (137)
  5. GSK Faculty (119)
  6. Survivorship Research (114)

More Groups

People
  1. Robert Motzer (63)
  2. Alexander Drilon (53)
  3. Matthew Hellmann (38)
  4. Jedd Wolchok (33)
  5. Jonathan Rosenberg (33)
  6. Ghassan Abou-Alfa (30)

More People

Years
  1. 2021 (7)
  2. 2020 (152)
  3. 2019 (163)
  4. 2018 (140)
  5. 2017 (123)
  6. 2016 (94)

More Years

Publications
  1. Annals of Oncology (1052)
Publishers
  1. Oxford University Press (1052)

Results (1052)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preliminary safety, antitumor activity and pharmacodynamics results of HIT-IT MEDI1191 (mRNA IL-12) in patients with advanced solid tumours and superficial lesions
    Meeting Abstract

    Hamid, O.; Hellman, M.; Carneiro, B.; Marron, T.; Subbiah, V.; Mehmi, I.; Eyles, J.; Dubois, V.; Ridgway, B.; Hamid, O.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Concurrent mutations in STK11 and KEAP1 promote ferroptosis protection and SCD1 dependence in lung cancer
    Meeting Abstract

    Sen, T.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Postoperative ctDNA monitoring: A canary in a coalmine
    Editorial

    Lumish, M. A.; Tarazona, N.; Janjigian, Y. Y.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
    Guidelines

    Belli, C.; Penault-Llorca, F.; Ladanyi, M.; Normanno, N.; Scoazec, J. Y.; Lacroix, L.; Reis-Filho, J. S.; Subbiah, V.; Gainor, J. F.; Endris, V.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: The SANDPIPER trial
    Journal Article

    Dent, S.; Cortés, J.; Im, Y. H.; Diéras, V.; Harbeck, N.; Krop, I. E.; Wilson, T. R.; Cui, N.; Schimmoller, F.; Hsu, J. Y.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines
    Guidelines

    Lacouture, M. E.; Sibaud, V.; Gerber, P. A.; van den Hurk, C.; Fernández-Peñas, P.; Santini, D.; Jahn, F.; Jordan, K.; ESMO Guidelines Committe
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Expanding the nanotherapeutic toolbox for non-small-cell lung cancer
    Editorial

    Jee, J.; Li, B. T.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Low immunogenicity and favorable safety seen with novel regimen of tremelimumab (T) plus durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Kelley, R. K.; Negro, A.; Chen, C.; Ali, S.; Standifer, N.; Watras, M.; Evans, B.; Abou-Alfa, G. K.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) high-risk (HR) neuroblastoma (NB)
    Meeting Abstract

    Morgenstern, D. A.; Mora, J.; Chan, G. C.; Nysom, K.; Bear, M.; Worsaae Dalby, L.; Lisby, S.; Kushner, B. H.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)
    Meeting Abstract

    Sacco, J. J.; Carvajal, R.; Butler, M. O.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A.; Hernandez-Aya, L.; Nathan, P.; Hamid, O.; Piulats Rodriguez, J. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save